JTCS Email Content Delivery
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Personal Folders
Right arrow Download to citation manager
Right arrow Permission Requests
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Bortolotti, U.
Right arrow Articles by Gallucci, V.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bortolotti, U.
Right arrow Articles by Gallucci, V.

The Journal of Thoracic and Cardiovascular Surgery, Vol 94, 200-207, Copyright © 1987 by The American Association for Thoracic Surgery and The Western Thoracic Surgical Association


ARTICLES

Early mechanical failures of the Hancock pericardial xenograft

U Bortolotti, A Milano, G Thiene, F Guerra, A Mazzucco, M Valente, E Talenti and V Gallucci

From August 1981 to July 1984, a total of 97 Hancock pericardial xenografts were implanted in 84 patients, whose ages ranged from 13 to 75 years (mean 55.7 +/- 13). Mitral value replacement was performed in 17, aortic valve replacement in 54, and mitral-aortic valve replacement in 13. Operative survivors were reevaluated from July to September 1985. Cumulative duration of follow-up is 167 patient-years (range 0.5 to 4.1 years), and follow-up is 99% complete. The overall late mortality (at 4 years) is 3.6% +/- 1.4% per patient year, and the actuarial survival rate is 95.4% +/- 3% for aortic valve replacement, 74.7% +/- 16.5% for mitral valve replacement, and 67.1% +/- 20.7% for mitral-aortic valve replacement. One patient sustained a thromboembolic event after mitral valve replacement, but no such complications occurred after aortic or mitral-aortic valve replacement. Actuarial freedom from embolism at 4 years is 100% for aortic and mitral-aortic valve replacement and 93.3% +/- 6.4% for mitral valve replacement. Reoperation for Hancock pericardial xenograft dysfunction was performed in seven patients (five aortic and two mitral-aortic). In the aortic valve replacement group the causes were endocarditis in one, paravalvular leak in one, and primary tissue failure in three; all survived reoperation. The two patients with mitral-aortic valve replacement required reoperation because of primary tissue failure of both Hancock pericardial xenografts, and one died. All values explanted because of primary tissue failure showed commissural tears causing severe prosthetic regurgitation. Calcium deposits were severe in one and mild but unrelated to the cusp rupture in another. Collagen disarray was seen only at the site of the tears, whereas the collagen structure was well preserved in the intact parts of the cusps. Four patients with aortic valve replacement and one with mitral valve replacement show evidence of Hancock pericardial xenograft failure and are awaiting reoperation. The actuarial freedom from primary tissue failure at 4 years is 74.3% +/- 9.8% for aortic and 78.9% +/- 13.2% for mitral Hancock pericardial xenografts. At medium-term follow-up, the Hancock pericardial xenograft has shown poor durability and an extremely high rate of early mechanical failure, especially in the aortic position. These observations suggest the need for a close follow- up of Hancock pericardial xenograft recipients and possibly elective reoperation in asymptomatic patients with clinical evidence of prosthetic failure. These results have led us to discontinue the clinical use of this pericardial xenograft.


This article has been cited by other articles:


Home page
Ann. Thorac. Surg.Home page
A. D. Milano, C. Blanzola, G. Mecozzi, A. D'Alfonso, M. De Carlo, C. Nardi, and U. Bortolotti
Hemodynamic performance of stented and stentless aortic bioprostheses
Ann. Thorac. Surg., July 1, 2001; 72(1): 33 - 38.
[Abstract] [Full Text] [PDF]


Home page
Ann. Thorac. Surg.Home page
U. Bortolotti, G. Scioti, A. Milano, M. De Carlo, R. Codecasa, C. Nardi, and G. Tartarini
Performance of 21-mm size perimount aortic bioprosthesis in the elderly
Ann. Thorac. Surg., January 1, 2000; 69(1): 47 - 50.
[Abstract] [Full Text] [PDF]


Home page
J Biomater ApplHome page
J. M. G. Paez and E. Jorge-Herrero
Assessment of Pericardium in Cardiac Bioprostheses: A Review
J Biomater Appl, April 1, 1999; 13(4): 351 - 388.
[Abstract] [PDF]


Home page
J. Thorac. Cardiovasc. Surg.Home page
D. M. Cosgrove, B. W. Lytle, P. C. Taylor, M. T. Camacho, R. W. Stewart, P. M. McCarthy, D. P. Miller, M. R. Piedmonte, and F. D. Loop
The Carpentier-Edwards pericardial aortic valve: Ten-year results
J. Thorac. Cardiovasc. Surg., September 1, 1995; 110(3): 651 - 662.
[Abstract] [Full Text]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
ANN THORAC SURG ASIAN CARDIOVASC THORAC ANN EUR J CARDIOTHORAC SURG
J THORAC CARDIOVASC SURG ICVTS ALL CTSNet JOURNALS
Copyright © 1987 by The American Association for Thoracic Surgery.